ArticleFrontiers in oncology2026
A case report of primary hepatoid adenocarcinoma of the vagina and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatoid adenocarcinoma (HAC) is a rare extrahepatic malignant tumor that exhibits histological features resembling those of hepatocellular carcinoma. It is typically accompanied by an abnormal elevation in serum alpha - fetoprotein (AFP) levels. HAC can occur in multiple organs, with the stomach being the most common site. It has also been reported in organs such as the esophagus, colon, pancreas, lung, ovary, and uterus. After reviewing the relevant literature, to date, there have been no reports of primary HAC in the vagina. This article presents the first case of primary vaginal hepatoid adenocarcinoma. The patient was a post - menopausal elderly woman. By presenting the characteristics of the disease onset, clinical manifestations, clinicopathological features, molecular characteristics, and the treatment process, and through a literature review, the objective is to improve the understanding of this rare disease and offer a reference for clinical diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.